Vaccines: Victims of Their Own Success?

Perhaps in no area is the divide between the developed and developing worlds as striking as it is for vaccines: While healthcare consumers in economically advantaged nations worry about risk, in developing nations compelling need forces a focus on potential benefit. "People in the United States want a quick solution, not prevention, so they prefer drugs to vaccines. Elsewhere, people are afraid of drugs and side effects, and prefer vaccines," says Shan Lu, a primary-care physician who has worked

Written byRicki Lewis
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Perhaps in no area is the divide between the developed and developing worlds as striking as it is for vaccines: While healthcare consumers in economically advantaged nations worry about risk, in developing nations compelling need forces a focus on potential benefit. "People in the United States want a quick solution, not prevention, so they prefer drugs to vaccines. Elsewhere, people are afraid of drugs and side effects, and prefer vaccines," says Shan Lu, a primary-care physician who has worked in many countries. He is developing an HIV vaccine at the University of Massachusetts, Amherst, where he is associate professor of infectious diseases and immunology.

In 2002, more than 2 million people died worldwide from vaccine-preventable illness, according to the World Health Organization (WHO) and the Geneva-based Global Alliance for Vaccines and Immunization (GAVI). While some healthcare consumers in privileged nations eschew vaccines because of side effects, real or perceived, elsewhere ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies